Jasper Therapeutics Inc

NASDAQ:JSPR  
3.19
+0.19 (+6.33%)
Earnings Announcements

Jasper Therapeutics Expects Current Cash And Cash Equivalents To Be Sufficient To Fund Planned Operating & Capital Expenditures Through Early 2023

Published: 03/18/2022 20:15 GMT
Jasper Therapeutics Inc (JSPR) - Jasper Therapeutics - Expects Current Cash and Cash Equivalents to Be Sufficient to Fund Planned Operating & Capital Expenditures Through Early 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.31

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.33

More details on our Analysts Page.